ProQR Therapeutics N.V. (PRQR) Stock
Healthcare · Biotechnology · Member of Other US Stocks
ProQR Therapeutics N.V. (PRQR) closed at USD 1.47 on 2026-10-14, a change of -48.4 % over the past year, with a market capitalization of USD 204.62M.
ProQR Therapeutics N.V. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.47 |
| 2026-10-13 | 1.48 |
| 2026-10-12 | 1.62 |
| 2026-10-09 | 1.63 |
| 2026-10-08 | 1.57 |
| 2026-10-07 | 1.63 |
| 2026-10-06 | 1.65 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
ProQR Therapeutics N.V. key figures
- Previous close
- USD 1.47 (2026-10-14)
- 1-year change
- -48.4 %
- Market cap
- USD 204.62M
- Enterprise value
- USD 102.81M
- P/E ratio (trailing)
- -3.22
- P/E ratio (forward)
- -3.07
- EPS (trailing)
- -0.45
- EPS (forward)
- -0.47
- PEG ratio
- n/a
- Price to book
- 2.30
- Revenue growth
- 120.4 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 4.76
- Employees
- 186
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for ProQR Therapeutics N.V. and compare it with other stocks.
Analyze PRQRAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell ProQR Therapeutics N.V. shares.